New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
16:03 EDTQGENQIAGEN receives FDA approval of artus CMV RGQ MDx kit
QIAGEN N.V. announced that its artus CMV RGQ MDx Kit for human cytomegalovirus, or CMV, has been approved by the FDA under a full premarket approval, or PMA. The test is the only FDA-approved PCR-based assay optimized for low- to mid-throughput testing of CMV. With a turn-around time of approximately three hours, the assay provides faster results than other PMA approved tests. artus CMV RGQ MDx runs on QIAGEN's Rotor-Gene Q MDx real-time PCR platform, which was cleared by the FDA in 2012 and is a member of the QIAsymphony modular family of automated instruments.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
16:12 EDTQGENQIAGEN sees Q3 adjusted EPS 29c-30c, consensus 29c
Subscribe for More Information
16:11 EDTQGENQIAGEN sees FY15 adjusted EPS $1.16-1.18, consensus $1.10
Sees FY15 adjusted net sales to rise approximately 4% CER in 2015, as growth of about 7-8% CER in the core portfolio exceeds the adverse impact of approximately 3-4 percentage points from lower U.S. HPV sales. FY15 revenue consensus $1.32B.
16:09 EDTQGENQIAGEN reports Q2 adjusted EPS 26c, consensus 25c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use